✦ LIBER ✦

Rentech continues its GTL licensing spree

Publisher: Elsevier Science
Year: 2003
Weight: 33 KB
Volume: 2003
Category: Article
ISSN: 1351-4180
DOI: 10.1016/s1351-4180(03)00823-7

No coin nor oath required. For personal study only.

✦ Synopsis

development and production of pharmaceutical intermediates. AHF integrates the introduction of versatile aldehyde functionality with the formation of a chiral centre. Dow's new generation of chiral bisphosphite ligands is claimed to expand the scope of the technology beyond the vinylarene substrates.

📜 SIMILAR VOLUMES

Rentech in another GTL licensing move

📂 Article 📅 2003 🏛 Elsevier Science ⚖ 35 KB

are competitive and has joined up with Genencor to develop a bio-based route.

Rentech to license floating GTL technolo

Rentech to license floating GTL technology

📂 Article 📅 2003 🏛 Elsevier Science ⚖ 31 KB

R&D costs rose by 5% to DKR 713 M for 2002. The group generated profit of DKR 644 M after tax for 2002. Headquartered in Denmark, Novozymes A/S is a biotech-based world leader in enzymes and microorganisms for industrial use. Novozymes also applies its core competences in selected pharmaceutical are

Rentech awarded sixteenth patent related

Rentech awarded sixteenth patent related to its GTL process

📂 Article 📅 2003 🏛 Elsevier Science ⚖ 33 KB